Li Chiu Lu

US Patent:

6143289, Nov 7, 2000

Filed:

Dec 9, 1992

Appl. No.:

7/987638

Inventors:

Hal E. Broxmeyer - Indianapolis IN
Scott Cooper - Indianapolis IN
Charles Mantel - Indianapolis IN
Li Lu - Indianapolis IN

Assignee:

Indiana University Foundation - Bloomington IN

International Classification:

A61K 3819
C07K 1452

US Classification:

424 852

Abstract:

Described are preferred processes for suppressing proliferation of or for myeloprotecting myeloid cells in mammals. The processes involve the use of chemokines of the group Macrophage Inflammatory Protein-2. alpha. (MIP-2. alpha. ), Platelet Factor 4 (PF4), Interleukin-8 (IL-8) and Macrophage Chemotactic and Activating Factor (MCAF), or involve the use of these chemokines or Macrophage Inflammatory Protein-1. alpha. (MIP-1. alpha. ) in synergistic combinations or while they are substantially completely in monomeric form (i. e. substantially free from their polymerized or aggregated forms).

US Patent:

61654590, Dec 26, 2000

Filed:

Jun 7, 1995

Appl. No.:

8/474536

Inventors:

Hal E. Broxmeyer - Indianapolis IN
Scott Cooper - Indianapolis IN
Charles Mantel - Indianapolis IN
Li Lu - Indianapolis IN

Assignee:

Indiana University Foundation - Indianapolis IN

International Classification:

A61K 3819
A61K 3820

US Classification:

424 852

Abstract:

Described are preferred processes and compositions for suppressing myeloid cells in mammals. Preferred processes and compositions involve the use of chemokines in synergistic combinations or while they are substantially completely in monomeric form (i. e. substantially free from their polymerized or aggregated forms).